Yang S Wang

20220402988, Dec 22, 2022

Dec 4, 2020

17/777088

- Dallas TX, US
Yang Wang - Dallas TX, US

C07K 14/54
A61P 35/00
C12N 15/62

The invention provides novel fusion proteins and prodrugs of Interleukin 15, and compositions and methods of preparation thereof, that are useful in treating various diseases and disorders (e.g., hyperplasia, solid tumor or hematopoietic malignancy).

20220264571, Aug 18, 2022

Feb 26, 2021

17/186290

- Atlanta GA, US
Cecilia N. Nguyen - Hickory Creek TX, US
Harry Liu - Hudson OH, US
James P. Daves - Acworth GA, US
William D. Turczyn - Clinton NY, US
Yang Wang - Naperville IL, US
Mark Butler - Arlington Heights IL, US
Murari Lamsal - Charlotte NC, US
Jason E. Carter - Gardendale AL, US

H04W 72/04
H04W 16/28

The technologies described herein are generally directed to configuring carrier aggregation zones based on transmission information in a fifth generation (5G) network or other next generation networks. For example, a method described herein can include identifying, by carrier aggregation equipment including a processor, carrier transmission information corresponding to a first carrier signal and a second carrier signal. The method can further include analyzing, by the carrier aggregation equipment, the carrier transmission information to determine first overlap zone information representative of a first carrier overlap zone for the first carrier signal and the second carrier signal. Further, based on the first overlap zone information, the method includes facilitating configuring transmission parameter information representative of a transmission parameter applicable to transmission of the first carrier signal, to enable carrier aggregation by network equipment within the first carrier overlap zone.

20210340209, Nov 4, 2021

Apr 30, 2021

17/245679

- Dallas TX, US
Yang Wang - Dallas TX, US

C07K 14/55
C07K 14/715

The present invention includes proteins, nucleic acids and methods of making and using an activatable interleukin-2 (aIL2) comprising an Interleukin-2 (aIL2) fusion protein comprising: an Interleukin-2 (IL2) wild-type or mutein; a first cleavable linker; an interleukin-2 receptor binding region (IL2RB), and a half-life extender, such as an antibody Fc region, wherein cleavage of the cleavable linker releases the IL2 from the interleukin-2 receptor beta binding region.

20180072571, Mar 15, 2018

Jul 27, 2017

15/661412

- Branchburg NJ, US
- Paris, FR
- Dallas TX, US
- Fremont CA, US
Jean-Marc GIRARD - Versailles, FR
Zhiwen WAN - Plano TX, US
Glenn KUCHENBEISER - Newark DE, US
David ORBAN - Hampton NJ, US
Sean KERRIGAN - Princeton NJ, US
Reno PESARESI - Easton PA, US
Matthew Damien STEPHENS - Easton PA, US
Yang WANG - Glen Mills PA, US
Guillaume HUSSON - Wilmington DE, US

C01B 21/087
C04B 35/589
C04B 35/597
C04B 35/14
C09D 1/00
C01B 21/082
B05D 1/02
B05D 1/00
B05D 1/18
C23C 16/24

Solid or liquid N—H free, C-free, and Si-rich perhydropolysilazane compositions comprising units having the following formula [—N(SiH)(SiH-)], wherein x=0, 1, or 2 and y=0, 1, or 2 when x+y=2; and x=0, 1 or 2 and y=1, 2, or 3 when x+y=3 are disclosed. Also disclosed are synthesis methods and applications for the same.